Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Results published in the New England Journal of Medicine showed that the high dose of 750 mg/kg tested in a Phase IIIb/IV trial cut
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury